2026-04-18T05:53:46Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/58582025-10-24T10:39:15Zcom_2072_378070com_2072_378040col_2072_378092

Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology Gómez‑Caamaño, A. González‑San Segundo, C. Henríquez, I. Maldonado Pijoan, Javier Zapatero, A. Institut Català de la Salut [Gómez-Caamaño A] Radiation Oncology Department, Hospital Clínico Universitario de Santiago de Compostela, A Coruña, Spain. [González-San Segundo C] Radiation Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Henríquez I] Radiation Oncology Department, Hospital Universitario Sant Joan de Reus, Tarragona, Spain. [Maldonado X] Oncologia Radioteràpica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Zapatero A] Radiation Oncology Department, Hospital Universitario de La Princesa, Madrid, Spain Vall d'Hebron Barcelona Hospital Campus Pròstata - Càncer - Tractament DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant Other subheadings::Other subheadings::/therapy ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Clinical Decision-Making ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración Otros calificadores::Otros calificadores::/terapia TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::toma de decisiones clínicas Càncer de pròstata resistent a la castració; Oncologia de les radiacions; Consens Cáncer de próstata resistente a la castración; Oncología radioterápica; Consenso Castration-resistant prostate cancer; Radiation oncology; Consensus Background: The knowledge in the field of castration-resistant prostate cancer (CRPC) is developing rapidly, with emerging new therapies and advances in imaging. Nonetheless, in multiple areas there is still a lack of or very limited evidence, and clear guidance from clinicians regarding optimal strategy is required. Methods: A modified Delphi method, with 116 relevant questions divided into 7 different CRPC management topics, was used to develop a consensus statement by the URONCOR group. Results: A strong consensus or unanimity was reached on 93% of the proposed questions. The seven topics addressed were: CRPC definition, symptomatic patients, diagnosis of metastasis, CRPC progression, M0 management, M1 management and sequencing therapy, and treatment monitoring. Conclusions: The recommendations based on the radiation oncology experts' opinions are intended to provide cancer specialists with expert guidance and to standardise CRPC patient management in Spain, facilitating decision-making in different clinically relevant issues regarding CRPC patients. 2021-04-15T07:38:14Z 2021-04-15T07:38:14Z 2019-04 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Gómez-Caamaño A, González-San Segundo C, Henríquez I, Maldonado X, Zapatero A, Cabeza Rodríguez MA, et al. Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology. Clin Transl Oncol. 2019 Apr;21(4):420–32. 1699-3055 https://hdl.handle.net/11351/5858 10.1007/s12094-018-1940-2 30293231 000461394500004 http://hdl.handle.net/11351/5858 eng Clinical and Translational Oncology;21(4) https://link.springer.com/article/10.1007%2Fs12094-018-1940-2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf application/pdf Springer Scientia